Sonoma Pharmaceuticals Inc.
SNOA
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.97M
Close$
$-2.92
341.4% downside
Current Fair Value
341.4% downsideOvervalued by 341.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.97 Million |
|---|---|
| Enterprise Value | $5.85 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.79 |
| Beta | 1.29 |
| Outstanding Shares | 1,713,000 |
Return
| Return on Equity | -98.19% |
|---|---|
| Return on Assets | -24.74% |
| Return on Invested Capital | -33.98% |
Valuation & Multiples
| P/E Ratio | -0.58 |
|---|---|
| PEG | 4.93 |
| Price to Sales | 0.12 |
| Price to Book Ratio | 0.61 |
| Enterprise Value to Revenue | 0.33 |
| Enterprise Value to EBIT | -1.83 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1.1 |
| Debt to Equity | 1.87 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
February 10, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
$5.47 M
Average shareholder expectationNext Earnings Call
Expected Date
July 15, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$5.57 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.94%▼ 2.42% |
|---|---|
| Total Invested | $143,701▼ 63.75% |
| Investors Holding | 17▲ 2.00% |
ESG Score
No data
About Sonoma Pharmaceuticals Inc.
CEO: Amy Trombly